Atom | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

Funder: National Institutes of Health

Funding Amounts: Up to $499,000 direct costs per year; total direct costs for the 3-year project period may not exceed $750,000.

Summary: Supports pharmacodynamic, pharmacokinetic, and in vivo efficacy studies of neurotherapeutic agents to advance them toward further development for neurological or neuromuscular disorders.

Key Information: Clinical trials are not allowed; R61/R33 phased award mechanism; clear, quantitative milestones required for transition between phases.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

Sign in to see full grant listing